Animal Study Suggests Acetaminophen May Protect Against Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

SAN FRANCISCO-Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

SAN FRANCISCO—Research conducted at New York Medical College, Valhalla, shows that acetaminophen may prevent early biologic changes that can lead to colon cancer.

In the study, presented at the American Association for Cancer Research (AACR) annual meeting, rats were given low or high doses of 3,2´dimethyl-4-aminobiphenyl (DMAB), a chemical that mimics suspected human colon carcinogens (heterocyclic amines formed during cooking of protein), and acetaminophen or no acetaminophen.

In the animals given carcinogen alone, cellular changes that are common precursors to colon cancer were seen, in relationship to the dose. When the carcinogen was given after acetaminophen, the animals had significantly less cellular evidence of disease, especially gland cell hypertrophy and karyomegaly.

“In our study, even low levels of acetaminophen showed a powerful protective effect in colon cells exposed to DMAB,” said Gary M. Williams, MD, professor of pathology, New York Medical College, at an AACR poster session. “We noted these effects even in animals exposed to much higher doses of DMAB than a human would ever encounter.”

The study was funded in part by a research grant from McNeil Consumer Healthcare.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Related Content